bioAffinity Technologies annual stock-based compensation
2021
2022
2023
2024
2025
bioAffinity Technologies Stock-Based Compensation Growth & History (BIAF)
bioAffinity Technologies's stock-based compensation was $671,474 for fiscal 2025.
View full bioAffinity Technologies company overviewbioAffinity Technologies annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $671,474 | −$318,207 | −32.15% |
| 2024 | 2024-12-31 | $989,681 | $240,858 | +32.16% |
| 2023 | 2023-12-31 | $748,823 | $500,231 | +201.23% |
| 2022 | 2022-12-31 | $248,592 | $205,580 | +477.96% |
| 2021 | 2021-12-31 | $43,012 | — | — |
bioAffinity Technologies quarterly stock-based compensation
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $784,941 | $573,334 | +270.94% |
| Q1 2026 | 2026-03-31 | $14,340 | −$312,276 | −95.61% |
| Q4 2025 | 2025-12-31 | $66,119 | −$167,968 | −71.75% |
| Q3 2025 | 2025-09-30 | $67,132 | −$118,555 | −63.85% |
| Q2 2025 | 2025-06-30 | $211,607 | −$74,588 | −26.06% |
| Q1 2025 | 2025-03-31 | $326,616 | $42,904 | +15.12% |
| Q4 2024 | 2024-12-31 | $234,087 | −$423 | −0.18% |
| Q3 2024 | 2024-09-30 | $185,687 | −$758 | −0.41% |
| Q2 2024 | 2024-06-30 | $286,195 | $115,940 | +68.10% |
| Q1 2024 | 2024-03-31 | $283,712 | $126,099 | +80.01% |
| Q4 2023 | 2023-12-31 | $234,510 | $197,663 | +536.44% |
| Q3 2023 | 2023-09-30 | $186,445 | $107,432 | +135.97% |
| Q2 2023 | 2023-06-30 | $170,255 | $143,570 | +538.02% |
| Q1 2023 | 2023-03-31 | $157,613 | $51,566 | +48.63% |
| Q4 2022 | 2022-12-31 | $36,847 | — | — |
| Q3 2022 | 2022-09-30 | $79,013 | — | — |
| Q2 2022 | 2022-06-30 | $26,685 | — | — |
| Q1 2022 | 2022-03-31 | $106,047 | — | — |
bioAffinity Technologies stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, bioAffinity Technologies's stock-based compensation increased from $43,012 to $671,474, a change of $628,462. The latest reported quarter, Q2 2026, shows $784,941.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review bioAffinity Technologies source filings ↗